Details for:
-
Part-3/Pharm01_Raymon_Sec03_Ch03e_Diuretics.f4v
868.6 KB
-
Part-3/Pharm01_Raymon_Sec03_Ch07f_Ezetimbe.f4v
6.2 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch07g_Orlistat.f4v
7.4 MB
-
Part-1/Pharm1_Sec01_Ch01h_Calculations.f4v
9.9 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch04C_OtherDrugs.f4v
10.4 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch02b_Beta_Blockers.f4v
10.8 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch03g_IndicatonsForUseOfAntihypertensive.f4v
10.9 MB
-
Part-1/Pharm1_Sec01_Ch02a_Pharmadynamics.f4v
11.5 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch05a_RationaleForUse.f4v
13.0 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch07d_Nicotine_Acid_Niacin.f4v
13.7 MB
-
Part-1/Pharm1_Sec01_Ch02c_Quantal.f4v
16.2 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch07c_Bile_and_Sequestrants.f4v
16.5 MB
-
Part-1/Pharm1_Sec01_Ch01a_Pharmokinetics.f4v
17.1 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch07e_Gemfibrozil.f4v
19.2 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch06b_OsmoticDiuretics.f4v
19.8 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch02d_Ca_ChannelBlockers.f4v
22.4 MB
-
Part-1/Pharm1_Sec01_Ch02e_DrugDevelopment.f4v
22.8 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch03d_CalciumChannelBlockers.f4v
24.0 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch03h_TreatmentOfPulmonaryHyptension.f4v
27.6 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch07a_Antihyperlipidemics.f4v
33.2 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch07b_HMG-CoA_Reductase_Inhibitors.f4v
36.1 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch03a_DrugsStrategy.f4v
38.1 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch05b_Nitrates.f4v
39.0 MB
-
Part-2/Pharm01_Raymon_Sec02_Ch03c_IndirectActAdreenergicRecepAgnonists.f4v
40.1 MB
-
Part-1/Pharm1_Sec01_Ch01c_Absorbtion.f4v
42.0 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch06f_K_-SparingAgents.f4v
43.2 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch02c_K_ChannelBlockers.f4v
46.6 MB
-
Part-1/Pharm1_Sec01_Ch01g_SteadyState.f4v
47.9 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch04a_TheFailingHeart.f4v
50.8 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch01b_NA_Channels.f4v
50.9 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch02e_Unclassified.f4v
51.5 MB
-
Part-2/Pharm01_Raymon_Sec02_Ch02d_NIcotinicRecepAntagonists.f4v
51.7 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch06e_Thiazides.f4v
52.5 MB
-
Part-2/Pharm01_Raymon_Sec02_Ch04a_GlaucomaTreatment.f4v
53.4 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch06a_Diuretics.f4v
55.0 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch03f_AngiotensinConvertingInhibitors.f4v
55.5 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch03c_DirectActing_Vasodialators.f4v
56.4 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch05c_CCBs_BetaBlockers_Carvedilol.f4v
57.6 MB
-
Part-1/Pharm1_Sec01_Ch01f_Elimination.f4v
58.1 MB
-
Part-2/Pharm01_Raymon_Sec02_Ch03d_AlphaRecepAntagonists.f4v
60.5 MB
-
Part-2/Pharm01_Raymon_Sec02_Ch01c_PupillarySizeAccomodation_1.f4v
73.4 MB
-
Part-1/Pharm1_Sec01_Ch01d_Distribution.f4v
78.7 MB
-
Part-1/Pharm1_Sec01_Ch02d_Signaling.f4v
79.2 MB
-
Part-1/Pharm1_Sec01_Ch01e_Biotransformation.f4v
81.9 MB
-
Part-2/Pharm01_Raymon_Sec02_Ch02c_Muscarinic_RecepAntagonists.f4v
82.0 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch06c_CarbonicAnhydraseInhibitors.f4v
83.7 MB
-
Part-1/Pharm1_Sec01_Ch01b_Permeation.f4v
94.7 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch06d_LoopDiuretics.f4v
98.7 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch03b_DrugsAlteringSympatheticAct.f4v
99.0 MB
-
Part-1/Pharm1_Sec01_Ch02b_drCurves.f4v
103.0 MB
-
Part-2/Pharm01_Raymon_Sec02_Ch01a_AnatomyANS.f4v
108.1 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch01a_CardiacActionPotential.f4v
109.4 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch04b_Inotropes.f4v
123.2 MB
-
Part-2/Pharm01_Raymon_Sec02_Ch03e_BetaReceptorAntagonists.f4v
129.0 MB
-
Part-2/Pharm01_Raymon_Sec02_Ch04b_ANSPracticeProblems_01.f4v
130.2 MB
-
Part-3/Pharm01_Raymon_Sec03_Ch02a_NA_ChanneLBlockers.f4v
140.2 MB
-
Part-2/Pharm01_Raymon_Sec02_Ch01b_BloodPresureConMech.f4v
150.9 MB
-
Part-2/Pharm01_Raymon_Sec02_Ch02a_CholinericNeuroJunction.f4v
175.2 MB
-
Part-2/Pharm01_Raymon_Sec02_Ch03b_DirectActAdrenoceptorAgonists.f4v
190.8 MB
-
Part-4/Pharm01_Raymon_Sec04_Ch03a_Anticonvulsants.f4v
192.4 MB
-
Part-2/Pharm01_Raymon_Sec02_Ch03a_CatecholaminSynActionDegradation.f4v
197.7 MB
-
Part-2/Pharm01_Raymon_Sec02_Ch04b_ANSPracticeProblems_02.f4v
217.8 MB
-
Part-2/Pharm01_Raymon_Sec02_Ch02b_MuscarinicRecepActivat.f4v
247.6 MB